Unjha Formulations Limited (UNJHAFOR) Fair Value & Analysis
Healthcare · IN · Market cap ₹87.4M
Fair value as of: Jul 6, 2026
From 24 valuation models · updated today
Share price −8.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹17.55 – ₹28.85 · fair‑value band ₹23.31 – ₹39.32 · the ₹19.50 price screens below the ₹31.46 fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Unjha Formulations Limited (UNJHAFOR) currently trades at ₹19.50, while our model-based Fair Value estimate is ₹31.46 — implying the stock looks roughly 61.3% undervalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Unjha Formulations Limited generated revenue of ₹157M at a net margin of 4.5%. Revenue grew 39.2% year over year. It earns a return on equity of 20.2%. The stock trades on a trailing P/E of 12.4. Fundamentals as of Jul 6, 2026
Our scenario range runs from ₹23.31 (bear case) to ₹39.32 (bull case); at ₹19.50, the current price sits below that range. The share trades about 36% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside — at 61%, UNJHAFOR screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Unjha Formulations Limited engages in the manufacture and sale of ayurvedic products in India. It offers sat-isabgol and isabgo husk formulation in elaichi flavor under the Anchor name; and isabgol powder in orange flavor under the Fibron and Fibron SF names. The company also exports its products. Unjha Formulations Limited was incorporated in 1994 and is based in Sidhpur, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Unjha Formulations Limited reported revenue of ₹156M in FY2026 versus ₹142M in FY2022, a compound +2.4%/yr. Reported net income was ₹7.0M in FY2026, compounding +29.3%/yr from FY2022.
Is UNJHAFOR fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,514 | ₹1,329 | -71% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Unjha Formulations Limited (UNJHAFOR) undervalued?
What is the fair value of UNJHAFOR?
What is the quality score of UNJHAFOR?
What is the revenue of Unjha Formulations Limited (UNJHAFOR)?
What is the net profit margin of UNJHAFOR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.